Skip to main content
Year archive

Zur Rose Group AG — 2026 filings

All 32 regulatory filings released by Zur Rose Group AG (ROSE) in 2026, sourced directly from the official regulator.

32 Filings
2026 Period
2026 filings (32)
Filing Released Lang
2026 Annual General Meeting: Strong vote by shareholders in favour of continuity in leadership and strategy
Declaration of Voting Results & Voting Rights Announcements
2026-05-12 English
2026 Annual General Meeting: Strong vote by shareholders in favour of continuity in leadership and strategy
Declaration of Voting Results & Voting Rights Announcements
2026-05-12 English
Generalversammlung 2026: Starkes Votum der Aktionärinnen und Aktionäre für Kontinuität in Führung und Strategie
Declaration of Voting Results & Voting Rights Announcements
2026-05-12 German
Governance presentation
AGM Information
2026-04-22 English
DocMorris achieves strong revenue growth in Q1 2026 on track for EBITDA break-even
Earnings Release Q1 2026
2026-04-16 English
DocMorris achieves strong revenue growth in Q1 2026 – on track for EBITDA break-even
Earnings Release Q1 2026
2026-04-16 English
DocMorris mit starkem Umsatzwachstum im ersten Quartal 2026 – auf Kurs zum EBITDA-Breakeven
Earnings Release Q1 2026
2026-04-16 German
DocMorris publishes invitation to the Annual General Meeting
Proxy Solicitation & Information Statement
2026-04-16 English
DocMorris publiziert Einladung zur Generalversammlung
Proxy Solicitation & Information Statement
2026-04-16 German
Q1 2026 Trading Update Presentation
Investor Presentation
2026-04-16 English
DocMorris enhances its leading AI-powered health platform by partnering with Hello Inside to address metabolic healthcare
Regulatory Filings
2026-04-14 English
DocMorris and Google partner to advance one of Europes leading AI-powered digital health platform
Regulatory Filings
2026-03-19 English
DocMorris achieves 2025 targets – focus on profitability, growth and expansion of digital health platform
Earnings Release FY 2025
2026-03-19 English
DocMorris erreicht Ziele 2025 – Fokus auf Profitabilität, Wachstum und Ausbau der digitalen Gesundheitsplattform
Earnings Release FY 2025
2026-03-19 German
DocMorris and Google partner to advance one of Europe’s leading AI-powered digital health platform
Regulatory Filings
2026-03-19 English
DocMorris und Google gehen Partnerschaft ein, um eine der führenden KI-gestützten digitalen Gesundheitsplattformen Europas voranzutreiben
Regulatory Filings
2026-03-19 German
Annual Report 2025
Annual Report FY 2025
2026-03-19 English
Annual Results Presentation 2025
Investor Presentation
2026-03-19 English
DocMorris AG announces changes to its Board of Directors
Board/Management Information
2026-03-03 English
DocMorris AG announces changes to its Board of Directors
Board/Management Information
2026-03-03 English
DocMorris AG gibt Veränderungen im Verwaltungsrat bekannt
Board/Management Information
2026-03-03 German
DocMorris receives TUV certification for temperature-controlled delivery of pharmaceuticals
Regulatory Filings
2026-02-20 English
DocMorris and Infermedica simplify health: from symptoms to solutions with the AI health companion
Regulatory Filings
2026-02-12 English
Early redemption of the 6.875% Convertible Bonds due 2026
Capital/Financing Update
2026-02-02 English
Early redemption of the 6.875% Convertible Bonds due 2026
Capital/Financing Update
2026-02-02 English
Vorzeitige Rückzahlung der 6.875%-Wandelanleihe mit Fälligkeit 2026
Capital/Financing Update
2026-02-02 German
DocMorris repurchases convertible bonds maturing in 2026 with a nominal value of around CHF 14.4 million
Capital/Financing Update
2026-01-26 English
DocMorris repurchases convertible bonds maturing in 2026 with a nominal value of around CHF 14.4 million
Capital/Financing Update
2026-01-26 English
DocMorris kauft Wandelanleihen mit Fälligkeit 2026 im Nennwert von rund CHF 14.4 Mio. zurück
Capital/Financing Update
2026-01-26 German
DocMorris achieves 11.1 per cent revenue growth in 2025 strong fourth quarter
Earnings Release FY 2025
2026-01-20 English
DocMorris achieves 11.1 per cent revenue growth in 2025 – strong fourth quarter
Earnings Release FY 2025
2026-01-20 English
DocMorris erzielt 2025 Umsatzplus von 11.1 Prozent – starkes viertes Quartal
Earnings Release FY 2025
2026-01-20 German